Wells Fargo & Company Sangamo Therapeutics, Inc Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Wells Fargo & Company holds 64,973 shares of SGMO stock, worth $113,053. This represents 0.0% of its overall portfolio holdings.
Number of Shares
64,973
Previous 134,357
51.64%
Holding current value
$113,053
Previous $90,000
74.44%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding SGMO
# of Institutions
136Shares Held
86.5MCall Options Held
35.9KPut Options Held
156K-
Wasatch Advisors Inc Salt Lake City, UT20.1MShares$35 Million0.04% of portfolio
-
Armistice Capital, LLC New York, NY14.1MShares$24.5 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$20.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.7MShares$8.18 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA4.56MShares$7.94 Million0.01% of portfolio
About SANGAMO THERAPEUTICS, INC
- Ticker SGMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 156,552,992
- Market Cap $272M
- Description
- Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...